Exodus Point Capital Management, LP Bio N Tech Se Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$102.58 - $129.66 $1.51 Million - $1.91 Million	14,740 New	14,740 $1.59 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $6.13 Million - $9.63 Million	51,782 New	51,782 $7.78 Million
Q2 2022 Aug 19, 2022	SELL	$123.25 - $186.24 $636,463 - $961,743	-5,164 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$126.25 - $231.85 $651,955 - $1.2 Million	5,164 New	5,164 $881,000
Q4 2021 Feb 11, 2022	SELL	$216.64 - $362.52 $1.27 Million - $2.12 Million	-5,846 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $454,281 - $986,589	2,206 Added 60.6%	5,846 $1.6 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $173,719 - $370,204	1,533 Added 72.76%	3,640 $815,000
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $180,633 - $251,786	2,107 New	2,107 $230,000
Q4 2020 Feb 16, 2021	SELL	$72.71 - $129.54 $789,630 - $1.41 Million	-10,860 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$57.81 - $104.17 $627,816 - $1.13 Million	10,860 New	10,860 $752,000

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.6B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.